Inogen, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This annual filing reports full-year results; it does not provide a clear standalone fourth-quarter financial summary.
Business context
Inogen develops, manufactures, sells, and rents portable oxygen concentrators and related respiratory products. In September 2023, it acquired Physio-Assist, adding Simeox airway-clearance technology for bronchiectasis. The company generated 71.7% of 2023 revenue in the United States and 28.3% internationally.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $315.7 million | $377.2 million |
| Sales revenue | $251.6 million | $320.5 million |
| Rental revenue | $64.1 million | $56.7 million |
| Gross profit / gross margin | $126.7 million / 40.1% | $153.5 million / 40.7% |
| Operating loss | $109.4 million | $85.2 million |
| Net loss | $102.4 million | $83.8 million |
| Net loss per share | $4.42 | $3.67 |
| Cash from operating activities | $(3.2) million | $(37.5) million |
Sales gross margin was 37.0%, down from 38.3%; rental gross margin was 52.7%, down from 54.3%. Adjusted EBITDA, a non-GAAP measure, was a loss of $37.8 million versus a loss of $13.5 million.
At year-end, cash and cash equivalents were $125.5 million, marketable securities were $3.0 million, and working capital was $134.6 million, down from $239.3 million. Total liabilities were $121.4 million and stockholders’ equity was $204.8 million. The filing reports that acquired Physio-Assist bank loans were settled before year-end; it does not identify material outstanding borrowings in the balance-sheet presentation.
Investing cash outflow was $59.3 million, including $29.6 million for the Physio-Assist acquisition and $26.5 million for rental equipment and other property and equipment. The company says available liquidity and expected sales and rental cash generation should fund operating and investing needs for at least the next 12 months.
Material changes and unusual items
- Total revenue fell 16.3%. Sales of approximately 130,500 systems declined 23.5% from 170,500 in 2022. Lower direct-to-consumer sales reflected fewer sales representatives and reduced marketing; domestic and international business-to-business sales also declined.
- Rental revenue rose 13.0%, primarily with more patients on service and higher Medicare reimbursement rates. The oxygen rental patient base grew to approximately 51,900 from 45,600.
- A $32.9 million goodwill impairment was recorded in 2023 after the share-price decline reduced the company’s market capitalization below its carrying value.
- General and administrative expense rose 71.4% to $75.3 million, including a $6.8 million earnout fair-value expense, $3.4 million of restructuring and severance costs, and $3.4 million of CEO-transition costs. In 2022, an earnout fair-value benefit and a $52.2 million loss from abandoning the TAV program materially affected comparisons.
- Semiconductor-chip premiums in cost of sales were $14.2 million, down from $23.8 million in 2022. Management said these elevated costs were expected to affect cost of sales through the first half of 2024.
- Medicare’s non-rural non-CBA oxygen reimbursement rates were reduced effective January 1, 2024 after temporary blended rates expired. The filing identifies reimbursement policy as a material business risk.
Outlook, risks, and contingencies
No specific revenue, earnings, or margin guidance is provided. Management’s priorities include improving sales-force productivity, expanding rental revenue and provider relationships, growing international business, and developing products and clinical evidence. The company launched the Rove 6 in the U.S. in 2023 and planned to launch the Rove 4 in 2024. It is pursuing U.S. regulatory authorization for Simeox.
Key risks include Medicare and private-payor reimbursement changes, customer and Medicare concentration, competition and lower sales volumes, higher lead-generation costs, and reliance on single- or limited-source suppliers. The company also cites inflation, wage pressures, supply-chain disruption, product-liability and regulatory exposure, and integration and regulatory risks related to Physio-Assist. Approximately 13.1% of rental patients were in the capped period at year-end, up from 9.2% in 2022; such patients generally generate no rental reimbursement during months 37–60 while service obligations continue.
Outstanding purchase orders were approximately $83.0 million, due within one year. Potential earnout payments are up to $13.0 million for Physio-Assist and $31.4 million for New Aera if specified milestones are met. The filing reports a pending securities class action and related derivative complaints; it does not expect other ordinary-course proceedings to have a material adverse effect. Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting; Physio-Assist was excluded from the internal-control assessment.
Important facts for investors to verify
- Whether sales volumes and direct-to-consumer performance stabilize, and whether rental growth offsets continued sales declines.
- How 2024 Medicare reimbursement-rate changes affect rental economics, patient additions, and the share of capped patients.
- Whether semiconductor and other component costs normalize after the first half of 2024, and whether single-source supply risks persist.
- Whether cash burn, acquisition integration, and planned cost reductions support management’s stated 12-month liquidity outlook.
- Progress toward Simeox U.S. regulatory clearance, achievement of earnout milestones, and any material developments in pending litigation.